Engineers Gate Manager’s Protagonist Therapeutics PTGX Stock Holding History

Engineers Gate Manager’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$536K	Buy	+4,373	New	+$457K	0.01%	1462
2025 Q2	–	Sell	-15,327	Closed	-$741K	–	2471
2025 Q1	$741K	Buy	+15,327	New	+$642K	0.01%	1232
2024 Q3	–	Sell	-12,707	Closed	-$440K	–	2344
2024 Q2	$440K	Sell	12,707 -24,863	-66%	-$728K	0.01%	1278
2024 Q1	$1.09M	Buy	37,570 +25,048	+200%	+$682K	0.03%	782
2023 Q4	$287K	Sell	12,522 -13,332	-52%	-$233K	0.01%	1478
2023 Q3	$431K	Buy	+25,854	New	+$502K	0.02%	1131
2023 Q2	–	Sell	-9,278	Closed	-$213K	–	1964
2023 Q1	$213K	Sell	9,278 -5,910	-39%	-$99.3K	0.01%	1401
2022 Q4	$166K	Buy	+15,188	New	+$128K	0.01%	1420
2022 Q3	–	Sell	-11,383	Closed	-$90K	–	1990
2022 Q2	$90K	Sell	11,383 -45,380	-80%	-$549K	﹤0.01%	1749
2022 Q1	$1.34M	Buy	+56,763	New	+$1.6M	0.05%	496
2021 Q3	–	Sell	-4,710	Closed	-$211K	–	1912
2021 Q2	$211K	Buy	+4,710	New	+$155K	0.01%	1377
2021 Q1	–	Sell	-13,030	Closed	-$263K	–	2068
2020 Q4	$263K	Buy	+13,030	New	+$280K	0.01%	1376

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Engineers Gate Manager's PTGX Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 4,373 shares worth $536K. The stake represents 0.01% of the portfolio and ranks #1462 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in PTGX as recently as Q1 2025.

Engineers Gate Manager first reported a position in PTGX in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.34M in Q1 2022. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Engineers Gate Manager held 4,373 shares of Protagonist Therapeutics worth $536K as of Q2 2026.
Protagonist Therapeutics was a new Engineers Gate Manager position in Q2 2026.
Protagonist Therapeutics made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1462 holding.
Engineers Gate Manager first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 12 quarters since.
Engineers Gate Manager's Protagonist Therapeutics position peaked at $1.34M in Q1 2022.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.